Logo

Celltrion Receives EC's Approval for Yuflyma (biosimilar- adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases

Share this

Celltrion Receives EC's Approval for Yuflyma (biosimilar- adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases

Shots:

  • The EC approval follows CHMP’s positive recommendation for Yuflyma (high concentration formulation) granted in Dec'2020. The approval covers all 13 intended indications to treat multiple chronic inflammatory diseases
  • The approval is based on analytical- pre/ clinical studies- demonstrating that Yuflyma is comparable to the reference product- in terms of safety- efficacy- PK/PD- and immunogenicity up to 24wks. and 1yr following treatment
  • The company will take ECDRP to minimize lead time to launch the product in the UK and remains committed to delivering innovative and affordable medications

 ­ Ref: Businesswire | Image: Celltrion

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions